GlassScriptPhysician profile
Jose L Marquez
NPI 1710956958
$19,642.84
in general payments reported to CMS, 2019-2025
35 companies · $1,494 in 2025
The $1,494 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,292 · 2020: $1,960 · 2021: $3,592 · 2022: $3,092 · 2023: $2,978 · 2024: $2,235 · 2025: $1,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,588 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,587.74 |
| Education | $119.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,714.90 | 2019-2025 | Aveir, Jot Dx, Gallant |
| Biotronik INC. | $4,016.13 | 2019-2023 | Acticor 7 Vr-T Dx |
| Esperion Therapeutics, INC. | $1,782.05 | 2020-2025 | Nexletol |
| Boston Scientific Corporation | $989.23 | 2019-2024 | Watchman Flx, Watchman Access System |
| Actelion Pharmaceuticals US, INC. | $827.40 | 2022-2025 | Opsumit, Uptravi |
| Pfizer INC. | $729.72 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $665.95 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $640.52 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $578.61 | 2019-2025 | |
| Amgen INC. | $485.92 | 2019-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $453.34 | 2021-2025 | Eliquis, Camzyos |
| Surmodics, INC. | $414.34 | 2022 | |
| Impulse Dynamics (USA) INC. | $373.63 | 2022-2023 | Optimizer |
| Medtronic Vascular, INC. | $296.94 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $258.05 | 2022-2025 | Verquvo |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Marquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.